BRPI1007945A2 - Composição farmacêutica, comprimido, e, métodos de tratar um paciente sofrendo de hepatite c, de reduzir um ou mais dos efeitos colaterais associados ao tratamento com nitazoxanida ou tizoxanida em um paciente, de aumentar a biodisponibilidade de nitazoxinida ou de um seu análogo em um paciente, e de prolongar a absorção de nitazoxanida ou de um seu análogo em um paciente - Google Patents

Composição farmacêutica, comprimido, e, métodos de tratar um paciente sofrendo de hepatite c, de reduzir um ou mais dos efeitos colaterais associados ao tratamento com nitazoxanida ou tizoxanida em um paciente, de aumentar a biodisponibilidade de nitazoxinida ou de um seu análogo em um paciente, e de prolongar a absorção de nitazoxanida ou de um seu análogo em um paciente

Info

Publication number: BRPI1007945A2
Authority: BR; Brazil
Prior art keywords: patient; nitazoxanide; nitazoxinide; tizoxanide; bioavailability
Prior art date: 2009-02-13

Application number

BRPI1007945-9A

Other languages

English (en)

Inventor

Jean-François Rossignol

Marc Ayers

Original Assignee

Romark Lab Lc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-02-13

Filing date

2010-02-12

Publication date

2015-09-01

2010-02-12 Application filed by Romark Lab Lc filed Critical Romark Lab Lc

2015-09-01 Publication of BRPI1007945A2 publication Critical patent/BRPI1007945A2/pt

2020-08-04 Publication of BRPI1007945B1 publication Critical patent/BRPI1007945B1/pt

2020-08-18 Publication of BRPI1007945B8 publication Critical patent/BRPI1007945B8/pt

2020-09-01 Publication of BRPI1007945C1 publication Critical patent/BRPI1007945C1/pt

2021-05-25 Publication of BRPI1007945C8 publication Critical patent/BRPI1007945C8/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Physiology (AREA)
Rheumatology (AREA)
Nutrition Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

BRPI1007945A 2009-02-13 2010-02-12 formulação farmacêutica de liberação controlada de nitazoxanida, tizoxanida ou uma combinação dos mesmos, e, comprimido de bicamada para administração oral BRPI1007945C8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US20228509P	2009-02-13	2009-02-13
US61/202285		2009-02-13
PCT/US2010/024000 WO2010093854A1 (en)	2009-02-13	2010-02-12	Controlled release pharmaceutical formulations of nitazoxanide

Publications (5)

Publication Number	Publication Date
BRPI1007945A2 true BRPI1007945A2 (pt)	2015-09-01
BRPI1007945B1 BRPI1007945B1 (pt)	2020-08-04
BRPI1007945B8 BRPI1007945B8 (pt)	2020-08-18
BRPI1007945C1 BRPI1007945C1 (pt)	2020-09-01
BRPI1007945C8 BRPI1007945C8 (pt)	2021-05-25

Family

ID=42560126

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1007945A BRPI1007945C8 (pt)	2009-02-13	2010-02-12	formulação farmacêutica de liberação controlada de nitazoxanida, tizoxanida ou uma combinação dos mesmos, e, comprimido de bicamada para administração oral

Country Status (23)

Country	Link
US (5)	US8524278B2 (pt)
EP (1)	EP2395840B1 (pt)
JP (3)	JP5726766B2 (pt)
KR (1)	KR101697800B1 (pt)
CN (2)	CN102395276A (pt)
AU (3)	AU2010213678B2 (pt)
BR (1)	BRPI1007945C8 (pt)
CA (1)	CA2752233C (pt)
CO (1)	CO6501159A2 (pt)
CY (1)	CY1123162T1 (pt)
DK (1)	DK2395840T3 (pt)
EA (1)	EA029018B1 (pt)
ES (1)	ES2797493T3 (pt)
HR (1)	HRP20201055T1 (pt)
HU (1)	HUE049501T2 (pt)
IL (1)	IL214624A0 (pt)
LT (1)	LT2395840T (pt)
MX (2)	MX381895B (pt)
PL (1)	PL2395840T3 (pt)
PT (1)	PT2395840T (pt)
SI (1)	SI2395840T1 (pt)
UA (1)	UA107564C2 (pt)
WO (1)	WO2010093854A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2422556T3 (es) *	2006-01-09	2013-09-12	Romark Lab Lc	Tratamiento de hepatitis vírica
JP5726766B2 (ja)	2009-02-13	2015-06-03	ロマークラボラトリーズエル．シー．	ニタゾキサニドの制御放出医薬配合物
EP2808019B1 (en) *	2012-01-27	2019-09-25	Siegfried Rhein S.A. De C.V.	Improved nitazoxanide composition and preparation method thereof
WO2013124768A1 (en) *	2012-02-20	2013-08-29	Lupin Limited	Bilayer tablet of dronedarone
KR101639692B1 (ko) *	2013-12-13	2016-07-14	제일약품주식회사	2 이상의 유효성분을 포함하는 구강 내 속붕해 다중유닛 약제학적 조성물
JP6633092B2 (ja)	2014-11-11	2020-01-22	ロマークラボラトリーズ，リミティドカンパニー	チゾキサニド、その類似体又は塩のプロドラッグを用いる組成物及び治療方法
CN108289961A (zh)	2016-03-31	2018-07-17	罗马克实验室有限公司	用于治疗病毒性感染的噻唑化物化合物
US10905680B2 (en) *	2016-04-11	2021-02-02	Genfit	Methods of treatment for cholestatic and fibrotic diseases
KR102410951B1 (ko) *	2016-04-11	2022-06-20	장피트	담즙정체성 및 섬유증 질환의 치료 방법
ES2958616T3 (es) *	2017-03-08	2024-02-12	Cinrx Pharma Llc	Formulaciones farmacéuticas de floroglucinol y trimetilfloroglucinol
CN110430876A (zh) *	2017-03-13	2019-11-08	基恩菲特公司	用于组合疗法的药物组合物
WO2018195035A1 (en)	2017-04-18	2018-10-25	Romark Laboratories L.C.	Inhibition of protein disulfide-isomerase a3
WO2018230711A1 (ja)	2017-06-16	2018-12-20	学校法人同志社	ｍＴＯＲインヒビターを含む、眼の症状、障害または疾患を治療または予防するための医薬およびその応用
EP3639855A4 (en) *	2017-06-16	2021-03-17	The Doshisha	COMPOUNDS HAVING CASPASE INHIBITORING ACTIVITY, PHARMACEUTICAL AGENT CONTAINING THEM FOR THE TREATMENT OR PREVENTION OF SYMPTOMS, DISORDERS OR DISEASES OF CORNEAL ENDOTHELIUM, AND APPLICATION OF SUCH PHARMACEUTICAL AGENT
CN108524460B (zh) *	2018-05-14	2021-01-01	佛山市南海东方澳龙制药有限公司	烯啶虫胺双层片
WO2019241376A1 (en)	2018-06-14	2019-12-19	The Trustees Of Columbia University In The City Of New York	Treatment of cognitive disorders using nitazoxanide (ntz), nitazoxanide (ntz) analogs, and metabolites thereof
CN110025621A (zh) *	2019-03-13	2019-07-19	中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心)	替唑尼特和硝唑尼特在制备抗炎药物中的应用
CN111012788B (zh) *	2019-12-12	2021-01-15	武汉职业技术学院	硝唑尼特和替唑尼特在制备抗猪繁殖与呼吸综合征病毒药物中的应用
KR20210079216A (ko) *	2019-12-19	2021-06-29	(주)셀트리온	시벤졸린 또는 이의 염을 포함하는 약학 제형
JP2023537237A (ja)	2020-07-20	2023-08-31	ロマークラボラトリーズ，リミティドカンパニー	チゾキサニドおよび２－ヒドロキシ－ｎ－（５－クロロ－１，３－チアゾル－２－イル）ベンズアミド（ｒｍ－４８４８）とエタノールアミン、モルホリン、プロパノールアミン、ピペラジン、およびｎ－メチルピペラジンの結晶塩
CN116367892A (zh)	2020-08-24	2023-06-30	罗马克实验室有限公司	噻唑化物抗冠状病毒的用途
WO2022130406A1 (en) *	2020-12-15	2022-06-23	Cipla Limited	Inhalation composition of nitazoxanide or its derivatives for use in coronavirus disease
GB2625684A (en)	2021-10-05	2024-06-26	Council Of Scient And Industrial Research An Indian Registered Body Incorporated Under The Regn Of S	An improved process for the preparation of nitazoxanide and intermediates thereof
CN114259492A (zh) *	2021-12-21	2022-04-01	中以海德人工智能药物研发股份有限公司	硝唑尼特在治疗乙肝中的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1437800A (en)	1973-08-08	1976-06-03	Phavic Sprl	Derivatives of 2-benzamido-5-nitro-thiazoles
JPH06316517A (ja) *	1993-02-22	1994-11-15	Grelan Pharmaceut Co Ltd	放出制御製剤
US5387598A (en) *	1994-04-13	1995-02-07	Rossignol; Jean-Francois	Composition and galenic formulation suitable for combatting affections of the lower abdomen
US5578621A (en) *	1994-09-08	1996-11-26	Romark Lab Lc	Benzamide derivatives
MX9604483A (es) *	1994-09-08	1998-02-28	Jean-Francois Rossignol	Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5968961A (en) *	1997-05-07	1999-10-19	Romark Laboratories, L.C.	Pharmaceutical compositions of tizoxanide and nitazoxanide
CZ298269B6 (cs) *	1997-05-07	2007-08-08	Romark Laboratories, L. C.	Orální farmaceutický prípravek
US5948440A (en)	1997-12-17	1999-09-07	Ranbaxy Laboratories Limited	Modified release matrix formulation of cefaclor and cephalexin
WO2000025752A1 (en)	1998-11-02	2000-05-11	Church, Marla, J.	Multiparticulate modified release composition
GB0009522D0 (en) *	2000-04-19	2000-06-07	Smithkline Beecham Plc	Composition
DE10031043A1 (de) *	2000-06-26	2002-02-14	Bayer Ag	Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
JP4637338B2 (ja) *	2000-09-22	2011-02-23	大塚製薬株式会社	シロスタゾール有核錠
CN1466451B (zh)	2000-09-29	2010-05-12	索尔瓦药物有限公司	不受离子强度影响的持续释放的医药制剂
US7074417B2 (en)	2000-10-13	2006-07-11	Advancis Pharmaceutical Corporation	Multiple-delayed release anti-viral product, use and formulation thereof
CN1596104A (zh)	2001-09-28	2005-03-16	麦克内尔-Ppc股份有限公司	改进的释放剂型
EP1435931A2 (en)	2001-09-28	2004-07-14	Sun Pharmaceuticals Industries Ltd.	Dosage form for treatment of diabetes mellitus
US7985422B2 (en) *	2002-08-05	2011-07-26	Torrent Pharmaceuticals Limited	Dosage form
TW200517127A (en)	2003-08-07	2005-06-01	Sb Pharmco Inc	Novel composition
GB0319874D0 (en) *	2003-08-22	2003-09-24	Glaxo Group Ltd	Novel formulation
UA90864C2 (en)	2004-09-09	2010-06-10	Ромарк Лебораториз, Л.К.	Halogenated benzamide derivatives
WO2006070406A1 (en)	2004-12-29	2006-07-06	J.B. Chemicals & Pharmaceuticals Ltd	Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof
US20070015803A1 (en) *	2005-04-12	2007-01-18	Romark Laboratories L.C.	Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
FR2889811B1 (fr)	2005-08-19	2009-10-09	Sanofi Aventis Sa	Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
ES2422556T3 (es) *	2006-01-09	2013-09-12	Romark Lab Lc	Tratamiento de hepatitis vírica
JP2006335771A (ja) *	2006-09-22	2006-12-14	Takeda Chem Ind Ltd	徐放性製剤およびその製造方法
US20080299188A1 (en) *	2007-05-14	2008-12-04	Pfizer Inc.	Controlled release dosage forms combining immediate release and sustainted release of low-solubility drug
US20080286344A1 (en) *	2007-05-16	2008-11-20	Olivia Darmuzey	Solid form
ES2550755T3 (es) *	2007-08-03	2015-11-12	Romark Laboratories, L.C.	Compuestos de tiazolida sustituidos con alquilsulfonilo
JP5726766B2 (ja) *	2009-02-13	2015-06-03	ロマークラボラトリーズエル．シー．	ニタゾキサニドの制御放出医薬配合物

2010
- 2010-02-12 JP JP2011550246A patent/JP5726766B2/ja active Active
- 2010-02-12 CN CN2010800164251A patent/CN102395276A/zh active Pending
- 2010-02-12 WO PCT/US2010/024000 patent/WO2010093854A1/en not_active Ceased
- 2010-02-12 ES ES10741758T patent/ES2797493T3/es active Active
- 2010-02-12 AU AU2010213678A patent/AU2010213678B2/en not_active Ceased
- 2010-02-12 PL PL10741758T patent/PL2395840T3/pl unknown
- 2010-02-12 LT LTEP10741758.6T patent/LT2395840T/lt unknown
- 2010-02-12 KR KR1020117020973A patent/KR101697800B1/ko not_active Expired - Fee Related
- 2010-02-12 HU HUE10741758A patent/HUE049501T2/hu unknown
- 2010-02-12 EP EP10741758.6A patent/EP2395840B1/en active Active
- 2010-02-12 CN CN201710263825.6A patent/CN107260695A/zh active Pending
- 2010-02-12 US US12/656,704 patent/US8524278B2/en not_active Expired - Fee Related
- 2010-02-12 MX MX2017006915A patent/MX381895B/es unknown
- 2010-02-12 BR BRPI1007945A patent/BRPI1007945C8/pt not_active IP Right Cessation
- 2010-02-12 EA EA201190127A patent/EA029018B1/ru not_active IP Right Cessation
- 2010-02-12 CA CA2752233A patent/CA2752233C/en not_active Expired - Fee Related
- 2010-02-12 PT PT107417586T patent/PT2395840T/pt unknown
- 2010-02-12 HR HRP20201055TT patent/HRP20201055T1/hr unknown
- 2010-02-12 MX MX2011008530A patent/MX348282B/es active IP Right Grant
- 2010-02-12 SI SI201032014T patent/SI2395840T1/sl unknown
- 2010-02-12 DK DK10741758.6T patent/DK2395840T3/da active
- 2010-12-02 UA UAA201110567A patent/UA107564C2/uk unknown
2011
- 2011-08-11 IL IL214624A patent/IL214624A0/en active IP Right Grant
- 2011-09-07 CO CO11115308A patent/CO6501159A2/es not_active Application Discontinuation
2013
- 2013-07-30 US US13/954,184 patent/US9351937B2/en not_active Expired - Fee Related
2015
- 2015-04-01 JP JP2015075264A patent/JP6117845B2/ja not_active Expired - Fee Related
2016
- 2016-02-16 AU AU2016200971A patent/AU2016200971B2/en not_active Ceased
- 2016-04-29 US US15/141,921 patent/US9827227B2/en not_active Expired - Fee Related
- 2016-12-09 JP JP2016239374A patent/JP6491174B2/ja not_active Expired - Fee Related
2017
- 2017-05-11 AU AU2017203148A patent/AU2017203148B2/en not_active Ceased
- 2017-11-16 US US15/814,850 patent/US10383855B2/en active Active
2019
- 2019-07-02 US US16/460,161 patent/US11426388B2/en active Active
2020
- 2020-07-07 CY CY20201100626T patent/CY1123162T1/el unknown

Also Published As

Publication number	Publication date
BRPI1007945C8 (pt)	2021-05-25
SI2395840T1 (sl)	2020-08-31
PT2395840T (pt)	2020-07-06
AU2017203148B2 (en)	2018-08-09
US20160243087A1 (en)	2016-08-25
CO6501159A2 (es)	2012-08-15
EA029018B1 (ru)	2018-01-31
US8524278B2 (en)	2013-09-03
UA107564C2 (uk)	2015-01-26
CN102395276A (zh)	2012-03-28
US11426388B2 (en)	2022-08-30
DK2395840T3 (da)	2020-06-08
US9827227B2 (en)	2017-11-28
US20180085353A1 (en)	2018-03-29
IL214624A0 (en)	2011-09-27
BRPI1007945B1 (pt)	2020-08-04
AU2016200971B2 (en)	2017-02-23
KR101697800B1 (ko)	2017-01-18
JP6491174B2 (ja)	2019-03-27
AU2016200971A1 (en)	2016-03-03
US20100209505A1 (en)	2010-08-19
CN107260695A (zh)	2017-10-20
EP2395840A4 (en)	2013-12-25
US20190321338A1 (en)	2019-10-24
LT2395840T (lt)	2020-07-10
BRPI1007945B8 (pt)	2020-08-18
WO2010093854A1 (en)	2010-08-19
MX381895B (es)	2025-03-13
MX2011008530A (es)	2011-10-14
AU2010213678A1 (en)	2011-09-01
US10383855B2 (en)	2019-08-20
AU2017203148A1 (en)	2017-06-01
CA2752233A1 (en)	2010-08-19
JP2012518002A (ja)	2012-08-09
MX348282B (es)	2017-06-05
AU2010213678B2 (en)	2015-11-26
JP6117845B2 (ja)	2017-04-19
JP2017061561A (ja)	2017-03-30
EA201190127A1 (ru)	2012-03-30
CA2752233C (en)	2017-01-03
BRPI1007945C1 (pt)	2020-09-01
US20140065215A1 (en)	2014-03-06
EP2395840A1 (en)	2011-12-21
ES2797493T3 (es)	2020-12-02
KR20120008024A (ko)	2012-01-25
JP2015143258A (ja)	2015-08-06
PL2395840T3 (pl)	2020-09-07
EP2395840B1 (en)	2020-04-15
HRP20201055T1 (hr)	2020-10-30
HUE049501T2 (hu)	2020-09-28
JP5726766B2 (ja)	2015-06-03
CY1123162T1 (el)	2021-10-29
US9351937B2 (en)	2016-05-31

Publication	Publication Date	Title
BRPI1007945A2 (pt)	2015-09-01	Composição farmacêutica, comprimido, e, métodos de tratar um paciente sofrendo de hepatite c, de reduzir um ou mais dos efeitos colaterais associados ao tratamento com nitazoxanida ou tizoxanida em um paciente, de aumentar a biodisponibilidade de nitazoxinida ou de um seu análogo em um paciente, e de prolongar a absorção de nitazoxanida ou de um seu análogo em um paciente
BRPI1014824A2 (pt)	2018-07-24	composição farmacêutica em forma de dose unitária e método de tratamento, prevenção ou redução da ocorrência de uma condição em um indivíduo
WO2011069141A3 (en)	2011-10-06	Interferon therapies in combination with blockade of stat3 activation
BRPI0906181A2 (pt)	2015-06-30	"método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer"
CL2013001654A1 (es)	2014-03-28	Compuestos derivados de 6-amino-2-fenilamino-1h-bencimidazol-5-carboxamida; composicion farmaceutica; y su uso en el tratamiento y/o prevencion de las enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
MY167691A (en)	2018-09-21	A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
MX2010004450A (es)	2010-05-05	Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119.
CL2008001125A1 (es)	2008-10-24	Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
BR112014014262A2 (pt)	2017-06-13	nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
HUE061596T2 (hu)	2023-07-28	Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
EP1848432A4 (en)	2009-12-30	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF PATHOLOGIES COMPRISING OBESITY, DIABETES, METABOLIC SYNDROMES, NEURODEGENERATIVE DISEASES, AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION
CL2013003372A1 (es)	2014-07-25	Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CL2008001126A1 (es)	2008-10-24	Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
AP2011005901A0 (en)	2011-10-31	Thienopyridine derivatives for the treatment and prevention of dengue virus infections.
BRPI1013705A2 (pt)	2016-04-05	compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
LT2013018A (lt)	2013-10-25	Farmacinė kompozicija, skirta gydyti diabetą ir metabolinius sutrikimus
MX2011007589A (es)	2011-08-17	Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
MX2010009270A (es)	2010-09-24	Compuestos y metodos para la prevencion o tratamiento de reestenosis.
GB2497453B (en)	2017-07-12	Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
CL2014003325A1 (es)	2015-04-24	Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer
IL228666A0 (en)	2013-12-31	Pharmaceutical compositions for preventing and/or treating an hiv disease in humans
PT2308497E (pt)	2014-07-24	Composição farmacêutica com glicosaminoglicanos e sua utilização no tratamento das úlceras crónicas
ZA201001117B (en)	2011-11-30	The application of 5-methyl-1,3-benzenediol or derivatives thereof in the preparation of medicines and functional foods for treatment or prevention of depression
IL217519A (en)	2015-06-30	Tazarotene derivatives, pharmaceutical compositions comprising them and use thereof for the manufacture of medicaments for the treatment of skin disorders
WO2011106378A3 (en)	2011-11-24	Oral b12 therapy

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-03-26	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-08-20	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2020-03-24	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-06-30	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-08-04	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/08/2020, OBSERVADAS AS CONDICOES LEGAIS.
2020-08-18	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: REF. RPI 2587 DE 04/08/2020 QUANTO AO QUADRO REIVINDICATORIO.
2020-09-01	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: REF. RPI 2587 DE 04/08/2020.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/02/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2021-09-08	B15V	Prolongation of time limit allowed
2021-12-07	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 12A ANUIDADE.
2022-03-15	B24D	Patent annual fee: restoration after fee payment
2022-12-06	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 13A ANUIDADE.
2023-03-14	B24D	Patent annual fee: restoration after fee payment
2023-12-05	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 14A ANUIDADE.
2024-02-27	B24D	Patent annual fee: restoration after fee payment
2024-12-03	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 15A ANUIDADE.
2025-03-18	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2813 DE 03-12-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.